Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Treasury Shares for 7 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 79.45% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 79.45% increase, with the full-year FY2025 number at $1.3 million, up 79.45% from a year prior.
  • Treasury Shares was $1.3 million for Q4 2025 at Kymera Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.4 million in Q3 2025 to a low of $37745.0 in Q4 2021.
  • A 5-year average of $570480.4 and a median of $527379.5 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: plummeted 65.72% in 2021, then surged 646.7% in 2022.
  • Kymera Therapeutics' Treasury Shares stood at $37745.0 in 2021, then soared by 646.7% to $281843.0 in 2022, then skyrocketed by 110.45% to $593140.0 in 2023, then rose by 26.38% to $749604.0 in 2024, then soared by 79.45% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Treasury Shares are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.3 million (Q2 2025).